Skip to content
Log in
Sponsored Design Multi-Agent AI Systems Using MCP and A2A: Engineer your own Pyt Design Multi-Agent AI Systems Using MCP and A2A: Engineer your own Pyt

Author

Y. Khan

h-index 25 View on Semantic Scholar

We have 4 of 137 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Oct 2026

Design, synthesis, and biological evaluation of pyrimidine linked fused thiazole–isoxazole conjugates as dual cholinesterase inhibitors for Alzheimer’s disease

Abstract Alzheimer’s disease (AD) affects over 55 million individuals worldwide, yet approved pharmacotherapies remain limited to symptomatic relief. Dual inhibition of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) offers a validated approach to restoring cholinergic tone. However, structurally differen...

Y. Khan, Mujeeb Ul Naeem, Syeda Farwa Naqvi et al. · 0 citations
Oct 2026

Computationally Guided Design and Biological Evaluation of New Benzoxazole Bridged thiazole based 1,3-Oxazole Conjugates as Potential Anti-Alzheimer's Agents: Molecular Docking, DFT and sADMET Studies

Findings identify benzoxazole-oxazole linked thiazole molecular hybrids as promising lead scaffolds for the development of next-generation multifunctional therapeutics for the treatment of Alzheimer's disease.

Syeda Farwa Naqvi, Hina Sarfraz, Abdul Rehman et al. · 0 citations
Aug 2026

Identification, Design and Computational Insights of Hybrid Thiadiazole Linked Fused Thiazole-Isoxazole as Potent Dual Inhibitor of AChE/BChE Alzheimer's Disease

Alzheimer’s disease (AD), involves progressive cognitive impairment primarily associated with cholinergic dysfunction. Dual inhibition of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) continue to represent a validated and clinically relevant therapeutic approach for alleviating cholinergic deficits in...

Y. Khan, Hina Sarfraz, Azmatullah Khan et al. · 0 citations
Review Aug 2026

Multitargeted drug strategies for Alzheimer’s and Parkinson’s diseases

Recent advances in multitarget drug development for AD and PD targeting compounds targeting Aβ, BACE1, MAO-B, cholinesterases, metal-ion dyshomeostasis, oxidative stress, and inflammatory pathways are reviewed.

Azmatullah Khan, Abdullah Abdullah, Syeda Farwa Naqvi et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.